George Panagis
Overview
Explore the profile of George Panagis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panagis G, Vlachou S, Higuera-Matas A, Simon M
Front Behav Neurosci
. 2022 Jul;
16:967922.
PMID: 35874654
No abstract available.
2.
Katsidoni V, Tzatzarakis M, Karzi V, Thermos K, Kastellakis A, Panagis G
Behav Brain Res
. 2020 Jul;
394:112831.
PMID: 32721470
Physical exercise could be a protective factor against the development of substance use disorders; however, a number of preclinical studies report reward-enhancing effects of exercise for various drugs of abuse....
3.
Pitsilis G, Spyridakos D, Nomikos G, Panagis G
Front Pharmacol
. 2017 May;
8:225.
PMID: 28487656
Marijuana is currently the most commonly abused illicit drug. According to recent studies, cannabinoid use occurring prior to pregnancy can impact brain plasticity and behavior in future generations. The purpose...
4.
Fanarioti E, Mavrikaki M, Panagis G, Mitsacos A, Nomikos G, Giompres P
Int J Neuropsychopharmacol
. 2014 Dec;
18(6).
PMID: 25522428
Background: The endocannabinoid system interacts extensively with other neurotransmitter systems and has been implicated in a variety of functions, including regulation of basal ganglia circuits and motor behavior. The present...
5.
Panagis G, Mackey B, Vlachou S
Front Psychiatry
. 2014 Aug;
5:92.
PMID: 25132823
Over the last decades, the endocannabinoid system has been implicated in a large variety of functions, including a crucial modulation of brain-reward circuits and the regulation of motivational processes. Importantly,...
6.
Mavrikaki M, Schintu N, Nomikos G, Panagis G, Svenningsson P
Int J Neuropsychopharmacol
. 2014 May;
17(12):1981-93.
PMID: 24852388
Restless legs syndrome (RLS) and Parkinson's disease (PD) are movement disorders usually accompanied by emotional and cognitive deficits. Although D3/D2 receptor agonists are effective against motor and non-motor deficits in...
7.
Katsidoni V, Alexiou P, Fotiadou M, Pelecanou M, Sagnou M, Panagis G
Psychopharmacology (Berl)
. 2014 May;
231(23):4467-78.
PMID: 24838368
Rationale: Recent animal studies reported that curcumin, the active constituent of Curcuma longa, has several central actions and may attenuate morphine tolerance. Objectives: In the present study, we utilized the...
8.
Mavrikaki M, Schintu N, Kastellakis A, Nomikos G, Svenningsson P, Panagis G
Eur Neuropsychopharmacol
. 2013 Nov;
24(4):630-8.
PMID: 24275700
Bipolar disorder (BD) is a severe pathological condition with impaired reward-related processing. The present study was designed to assess the effects of two commonly used BD medications, the mood stabilizer...
9.
Katsidoni V, Kastellakis A, Panagis G
Int J Neuropsychopharmacol
. 2013 Jul;
16(10):2273-84.
PMID: 23830148
Δ(9)-tetrahydrocannabinol (Δ(9)-THC), the main psychoactive ingredient of marijuana, has led to equivocal results when tested with the intracranial self-stimulation (ICSS) procedure or the open-field test for motor activity, two behavioural...
10.
Papakosta V, Kalogerakou S, Kontis D, Anyfandi E, Theochari E, Boulougouris V, et al.
Behav Brain Res
. 2013 Jan;
243:176-83.
PMID: 23327741
Objective: The serotonergic system is implicated in the pathophysiology of obsessive-compulsive disorder (OCD). However, the distinct role of serotonin (5-HT) receptor subtypes remains unclear. This study investigates the contribution of...